Impact of the U.S. 2025 tariff policy on Canadian pharmaceutical exports to the U.S.
Canadian domestic exports will decline by a significant proportion, and Canada will likely cease to re-export drugs to the U.S. once the tariff policy is in effect. The U.S. market may suffer from a supply shortage. Meanwhile, Canadian pharmaceutical manufacturers will be adversely affected due to reduced U.S. demand.
Authors
- Daphne Guh (ORCID: https://orcid.org/0000-0002-0209-5520)
- Aslam H. Anis (ORCID: https://orcid.org/0000-0003-0323-8885)
- Wei Zheng Zhang
- Yufan Hu
Institutions
- Center for Advancing Health (US)
- Centre for Advancing Health Outcomes (CA)
Publication Details
- Journal
- Health Policy
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1016/j.healthpol.2026.105594
- Primary Topic
- Canadian Policy and Governance
- Type
- article
- Field-Weighted Citation Impact
- 0.00